Outlook Therapeutics is a pre-commercial biopharmaceutical company dedicated to developing therapies for the preservation of vision. The company works on the development of an FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, specifically for conditions like wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), and branch retinal vein occlusion (BRVO).

Outlook Therapeutics

Outlook Therapeutics, Inc. | 9,877 followers on LinkedIn. ONS-5010: A uniquely positioned anti-VEGF therapy for wet AMD, DME and BRVO | Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab-vikg for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab-vikg for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan and other markets. Outlook Therapeutics expects to file ONS-5010 with the U.S.

Yezan Haddadin

Head of IT at Outlook Therapeutics, Inc.

Christoph Puetz

Senior Director, Drug Product Operations at Outlook Therapeutics, Inc.

Edwin Chan

Tony Moses

Outlook Therapeutics, Inc.

Our commitment to advancing retinal therapies is fueled by our passionate team. Discover their stories: https://bit.ly/4ccRdTD #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference. https://bit.ly/3UF53Id #wetAMD #ophthalmology #retinadisease

Thousands of people with a serious eye disease could be set to benefit after NICE today recommended a new treatment option. Find out more about bevacizumab gamma for treating wet age-related macular degeneration: https://lnkd.in/eJ3TsQHU #NICENews

NICE - National Institute for Health and Care Excellence

Did you know that #WetAMD is an advanced form of age-related macular degeneration? It occurs when abnormal blood vessels grow under the retina, leaking fluid and blood. This can cause swelling and damage to the macula, potentially leading to vision loss. #OTLK #Ophthalmology #RetinaDisease

Interested in our clinical progress? Learn more here: https://bit.ly/3XsbOiy #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics® Participates in a Virtual Investor CEO Connect Segment. https://bit.ly/4f7cHTB #wetAMD #ophthalmology #retinadisease

We are led by a proven team with extensive experience in the development and commercialization of ophthalmic therapeutics. Explore our backgrounds here: https://bit.ly/47dT9IJ . #OTLK #ophthalmology #retinadisease #wetAMD

Outlook Therapeutics is dedicated to developing therapies for the preservation of vision. #OTLK #ophthalmology #retinadisease #wetAMD

Stay in the loop! Be the first to know about our latest updates and announcements. Join us today! https://bit.ly/48ZjFXP #OTLK #Ophthalmology #RetinaDisease #WetAMD

#TuneInToday for our presentation at the Virtual Investor Closing Bell Event at 4 PM ET. Register here: https://bit.ly/4e2hsOj #OTLK #Ophthalmology #RetinaDisease #WetAMD

Viewport Meta

IPhone / Mobile Compatible

Apple Mobile Web Clips Icon

HSTS

Google Analytics

Google Maps

Content Delivery Network

WordPress

Organization Schema

Sitelinks Search Box

Scott A. Canute

Executive Director of Physician Relations

Surendra Sharma

Senior Vice President

Jedd Comiskey

SVP Head of Europe of

Jeff Evanson

Chief Commercial Officer

Lawrence A. Kenyon

Chief Financial Officer

C. Russell Trenary

President & CEO

Alicia Tozier

Senior Vice President of Marketing and Market Access

Terry Dagnon

Chief Operations Officer

Hedge Fund Funded Companies

United States Biotechnology Companies (Top 10K)

East Coast Biopharma Companies

Biopharma Companies With Fewer Than 1000 Employees

Outlook Therapeutics develops an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, diabetic macular edema, and branch retinal vein occlusion. Their ophthalmic formulations also use in treating retinal diseases.

Syntone Ventures

Post-IPO Equity - Outlook Therapeutics

Great Point Partners

GMS Holdings

Post-IPO Debt - Outlook Therapeutics

Biolexis

Iselin

New Jersey

United States

North America

Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference

NICE backs first ophthalmic bevacizumab for NHS use

Outlook Therapeutics, Inc.'s (NASDAQ:OTLK) largest shareholders are individual investors with 31% ownership, private ...

Outlook Therapeutics: Speculative Buy With High Stakes In Anti-VEGF Market (NASDAQ:OTLK)

Outlook Therapeutics® to Present at the Virtual Investor Pitch Conference

Outlook Therapeutics® Reports Financial Results for Second Quarter Fiscal Year 2024 and Provides Corporate Update

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab ...

Outlook Therapeutics® Announces UK Submission of Marketing Authorization Application (MAA) for ONS-5010 as a ...

Outlook Therapeutics® Receives European Commission Marketing Authorization for LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD

United Kingdom

Europe

Pakistan

Asia

HTML5

Lightbox

Vimeo

Wordpress

Google Maps API

Google Compute Engine

Modernizr

Microsoft Outlook

jQuery

Office 365

news_impact_assignment_basic

key_people

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

merger_acquisitions

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 10, 2024 2:41 PM	c2687efd
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 10, 2024 2:41 PM	be67e4db
crunchbase trigger	general	Nov 10, 2024 2:41 PM	da063700
crunchbase profile	general	Nov 10, 2024 9:46 PM	8f31914f
li profile	general	Nov 10, 2024 2:41 PM	28308457
translate crunchbase fundingrounds	general	Nov 10, 2024 10:05 PM	51e1f0f2
peers	general	Nov 10, 2024 2:41 PM	4c8d409e
news basic	general	Nov 10, 2024 2:41 PM	459c7816
bundesanzeiger	filings
merger acquisitions	company_analysis
financials download nd	financials
private financials	financials

OUTL

COM:OUTLOOKTHERAPEUTICS

Outlook Therapeutics